Finanzen von Core Laboratories Inc (CLB)CLBCore Laboratories Inc

Core Laboratories Inc. (CLB) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Service, accounting for 75.7% of total sales, equivalent to $94.28M. Another important revenue stream is Product sales. Understanding this composition is critical for investors evaluating how CLB navigates market cycles within the Business Support Services industry.

Evaluating the bottom line, Core Laboratories Inc. maintains a gross margin of 15.58%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 7.35%, while the net margin is 4.65%. These profitability ratios, combined with a Return on Equity (ROE) of 9.12%, provide a clear picture of how effectively CLB converts its operational activities into shareholder value.

In the context of the broader market, CLB competes directly with industry leaders such as WTI and EGY. With a market capitalization of $571.26M, it holds a significant position in the sector. When comparing efficiency, CLB's gross margin of 15.58% stands against WTI's 40.26% and EGY's 41.00%. Such benchmarking helps identify whether Core Laboratories Inc. is trading at a premium or discount relative to its financial performance.

Core Laboratories has shown some resilience with a recent Q2 EPS of $0.11, beating expectations by $0.02, despite a revenue decline of 4.3% year-over-year. Gross margin has fluctuated, with a recent figure of 15.58% in Q2 2026, down from 19.35% in Q3 2025, indicating some pressure on profitability.